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background: It is suggested that vascular inflammation after drug eluting stent (DES) implantation may be major determinant factor of 
occurrence of major adverse cardiac event (MACE) among patients who underwent DES implantation. However, there are no established 
tool to estimate that inflammation.
methods: Paired CRP (baseline, and 8-12 months after PCI as late-phase) was available in 1190 patients who underwent PCI with DES 
(first generation: sirolimus; 505 and paclitaxel; 328, second generation: everolimus; 196 and biolimus; 161). Elevated CRP was defined 
as over 0.2mg/dl. We investigated occurrence of MACE which comprises from all cause death, non-fatal myocardial infarction, and target 
lesion revascularization (TLR) among them.
results: Median of follow-up duration was 720 (interquartile range 272 to 1610) days. Of all, elevated CRP at baseline was seen in 38.1 
%, and it was decreased to 23.7% (including late-onset 9.3%) at late-phase. By survival analysis, occurrence of MACE was powerfully 
related to late-phase CRP (hazard ratio: HR; 3.93, 95% confidence interval: 95%CI; 3.07-5.05, P<0.0001) than baseline-CRP (HR; 1.63, 
95%CI; 1.27-2.08, P=0.0001). Multivariate analysis revealed that elevated late-phase CRP (HR; 3.38, 95%CI;2.45-4.66,P<0.0001), chronic 
kidney disease (CKD: eGFR<60ml/min; HR; 1.66, 95%CI; 1.21-2.28, P=0.002), number of diseased segment (HR;1.09, 95%CI; 1.02-1.17, 
P=0.01), and statin therapy (HR; 0.63, 95%CI; 0.45-0.89, P=0.01) were independent predictor of occurrence of MACE. Baseline CRP 
elevation (HR; 3.48, 95%CI; 2.47-4.90, P<0.001), CKD (HR; 1.75, 95%CI; 1.22-2.50, P=0.004), statin therapy (HR; 0.64, 95%CI; 0.44-0.94, 
P=0.02), and second generation DES (HR; 0.65, 95%CI; 0.44-0.98, P=0.04) was independent predictor of occurrence of late-phase CRP 
elevation.
Conclusion:  According to our results, late-phase CRP elevation was major determinant factor of long-term outcomes among patients 
who underwent DES implantation. Statin therapy and second generation DES may be effective among patients with either baseline CRP 
elevation or CKD, as high risk subset for late-phase CRP elevation.
